Literature DB >> 16273807

Rheumatoid arthritis registries in Sweden.

R F van Vollenhoven1, J Askling.   

Abstract

Patient registries provide valuable contributions to the field of rheumatology for both quality control and scientific purposes. With respect to the latter, patient registries are among the most important datasets used for longitudinal observational studies in rheumatic diseases, which are in turn an essential complement to data obtained from randomized, controlled trials. In Sweden a number of registries are available for such studies, ranging from general medical registries such as the in-patient registry, to rheumatoid arthritis (RA)-specific inception cohorts and biologics registries focusing on a specific patient population defined by a group of treatments. In recent years it has become particularly clear that questions regarding new therapies, their use in practice and their long-term safety, as well as aspects such as pharmacoeconomics, cannot fully be assessed using the data from clinical trials, and that registries are indispensible to obtain accurate answers to such questions. In this review we describe the Swedish rheumatology registries, including the Swedish RA registry and the Swedish biologics registries ARTIS (Antirheumatic Therapies Iin Sweden), SSATG (Southern Sweden Antirheumatic Therapy Group), and STURE (Stockholm Tumor Necrosis Factor-a Follow-up Registry). Data obtained from analyses based on these registries are reviewed. It is concluded that rheumatology registries are excellent tools for improving our knowledge base regarding rheumatic diseases.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16273807

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  15 in total

Review 1.  Biologics registers in RA: methodological aspects, current role and future applications.

Authors:  Elena Nikiphorou; Maya H Buch; Kimme L Hyrich
Journal:  Nat Rev Rheumatol       Date:  2017-06-01       Impact factor: 20.543

2.  Use of biological disease modifying antirheumatic drugs in rheumatoid arthritis in Austria from 2008 to 2011 : A retrospective analysis of 72% of the population.

Authors:  Tanja A Stamm; Berthold Reichardt; Jochen Zwerina; Valentin Ritschl; Valerie Nell-Duxneuner
Journal:  Wien Klin Wochenschr       Date:  2018-02-14       Impact factor: 1.704

3.  All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists.

Authors:  Loreto Carmona; Miguel Angel Descalzo; Eva Perez-Pampin; Dolores Ruiz-Montesinos; Alba Erra; Tatiana Cobo; Juan J Gómez-Reino
Journal:  Ann Rheum Dis       Date:  2007-02-26       Impact factor: 19.103

4.  Description of the registry of patients with ankylosing spondylitis in Turkey: TRASD-IP.

Authors:  Hatice Bodur; Sebnem Ataman; Derya Soy Buğdaycı; Aylin Rezvani; Kemal Nas; Kaan Uzunca; Emel Emlakçıoğlu; Altınay Göksel Karatepe; Bekir Durmuş; Melek Sezgin; Figen Ayhan; Pelin Yazgan; Tuncay Duruöz; Mahmut Yener; Alev Gürgan; Mehmet Kırnap; Engin Cakar; Lale Altan; Raikan Soydemir; Erhan Capkın; Ibrahim Tekeoğlu; Gülümser Aydın; Zafer Günendi; Barış Nacır; Ali Sallı; Cihat Oztürk; Asuman Memiş; Yasemin Turan; Erkan Kozanoğlu; Konçuy Sivrioğlu
Journal:  Rheumatol Int       Date:  2010-08-14       Impact factor: 2.631

5.  Predictors of Treatment Change Among Patients with Rheumatoid Arthritis Treated with TNF Inhibitors as First-Line Biologic Agent in the USA: A Cohort Study from Longitudinal Electronic Health Records.

Authors:  Yinzhu Jin; Joan E Landon; Whitney Krueger; Alexander Liede; Rishi J Desai; Seoyoung C Kim
Journal:  BioDrugs       Date:  2022-06-30       Impact factor: 7.744

Review 6.  The importance of rheumatology biologic registries in Latin America.

Authors:  Maria de la Vega; Hellen M da Silveira de Carvalho; Lucio Ventura Ríos; Maria V Goycochea Robles; Gustavo C Casado
Journal:  Rheumatol Int       Date:  2012-12-23       Impact factor: 2.631

7.  SveDem, the Swedish Dementia Registry - a tool for improving the quality of diagnostics, treatment and care of dementia patients in clinical practice.

Authors:  Dorota Religa; Seyed-Mohammad Fereshtehnejad; Pavla Cermakova; Ann-Katrin Edlund; Sara Garcia-Ptacek; Nicklas Granqvist; Anne Hallbäck; Kerstin Kåwe; Bahman Farahmand; Lena Kilander; Ulla-Britt Mattsson; Katarina Nägga; Peter Nordström; Helle Wijk; Anders Wimo; Bengt Winblad; Maria Eriksdotter
Journal:  PLoS One       Date:  2015-02-19       Impact factor: 3.240

8.  Factors influencing rheumatologists' prescription of biological treatment in rheumatoid arthritis: an interview study.

Authors:  Almina Kalkan; Kerstin Roback; Eva Hallert; Per Carlsson
Journal:  Implement Sci       Date:  2014-10-11       Impact factor: 7.327

9.  Ascendancy of weekly low-dose methotrexate in usual care of rheumatoid arthritis from 1980 to 2004 at two sites in Finland and the United States.

Authors:  T Sokka; T Pincus
Journal:  Rheumatology (Oxford)       Date:  2008-08-07       Impact factor: 7.580

10.  Randomized controlled trial of a nurse-led rheumatology clinic for monitoring biological therapy.

Authors:  Ingrid Larsson; Bengt Fridlund; Barbro Arvidsson; Annika Teleman; Stefan Bergman
Journal:  J Adv Nurs       Date:  2013-06-17       Impact factor: 3.187

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.